Journal Article Review Epublish
PubMed: 40791795 DOI: 10.1016/j.mtbio.2025.102148
Organoid-on-a-chip (OrgOC): Advancing cystic fibrosis research.
Mater Today Bio 34:102148
Authors: Minjie Zheng, Elisa Erice, Huiyi Wang, Lei Zhang, Charles H Lawrie
Affiliations
- School of Microelectronics, Shanghai University, Shanghai, 201800, China. Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, 201800, China.
- Sino-Swiss Institute of Advanced Technology (SSIAT), Shanghai University, Shanghai, 201800, China.
- Molecular Oncology Group, Biogipuzkoa Research Institute, Paseo Doctor Begiristain, San Sebastián, 20014, Spain.
Abstract
Cystic fibrosis (CF) is an autosomal recessive disorder resulting from impaired anion transport in the epithelium of multiple organs, thereby affecting various physiological functions throughout the body. The heterogeneity of CF complicates drug development, highlighting the growing importance of individualized therapies. CF patient-derived organoid models and organ-on-a-chip (OOC) platforms are promising in vitro models for recapitulating CF pathology, owing to their high simulation fidelity, individualized therapeutic capabilities, cost-effectiveness, and high-throughput screening potential. This review systematically summarizes the technological development pathways of patient-derived organoids and OOC platforms for CF, along with recent advances in their applications to CF-related basic research, and particularly focuses on exploratory studies using organoid-on-a-chip (OrgOC) systems to elucidate CF pathogenesis and assess therapeutic approaches.
MeSH
Fibrosis, Cystic Fibrosis, Organoids, Research, Therapeutics